Skip to main content
TipRanks
Go Ultimate75% OFF

Cuorips Inc. (4894) AI Stock Analysis

1 Followers
JP:4894

Cuorips Inc.

(TSE/TYO:4894)

Select Model
Rating:44Neutral
Price Target:JPY 5,432.00â–¼(-3.00% Downside)
Action:reiterated
Date:10/23/26

The overall score is low, driven primarily by poor financial performance and an unattractive valuation. The company is deeply unprofitable with significant cash burn, which is a major risk. Moderately positive technical trends provide some support but are insufficient to offset fundamental weaknesses.

Positive Factors
Zero DebtZero debt provides structural financial flexibility by eliminating interest obligations and reducing refinancing exposure. This gives Cuorips more capacity to absorb operating volatility and direct available resources toward investment while losses remain elevated.
Negative Factors
Revenue DeclineThe latest revenue contraction signals weakening business momentum and makes it harder to support fixed operating costs or fund development internally. If sales do not recover, the decline could prolong losses and increase reliance on existing financial resources.

Cuorips Inc. (4894) vs. iShares MSCI Japan ETF (EWJ)

-50%-25%0%25%50%75%100%JP:4894-8.94%EWJ+16.38%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
JPY 49.45B
Dividend Yield
―
Average Volume (3M)
142.47K
Price to Earnings (P/E)
-43.4
Beta (1Y)
1.22
Revenue Growth
-79.99%
EPS Growth
-58.51%
Country
Japan
Employees
51
Sector
General
Sector Strength
55
Industry
Biotechnology

Cuorips Inc. Business Overview & Revenue Model

Company Description

Cuorips Inc. specializes in the comprehensive lifecycle of iPS cell-derived cardiomyocyte sheets, undertaking their research, development, production, commercialization, and distribution. The firm's portfolio extends to include cellular, tissue-based...

Cuorips Inc. Financial Statement Overview

Summary

Financial performance is weak. While revenue growth is strong, escalating operating and net losses, declining gross margins, and deeply negative cash flows indicate a high-risk, unprofitable stage. The debt-free balance sheet is a positive, but it is overshadowed by the rapid cash burn.

Income Statement

22Negative

Balance Sheet

58Neutral

Cash Flow

18Very Negative
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue128.59M212.33M175.21M23.10M38.28M13.91M
Gross Profit5.13M45.90M91.56M-60.47M-57.64M-82.09M
EBITDA-1.12B-996.81M-513.57M-518.38M-371.78M-280.46M
Net Income-1.14B-1.02B-644.34M-632.18M-452.08M-375.34M
Balance Sheet
Total Assets4.81B5.12B5.74B6.18B3.59B4.04B
Cash, Cash Equivalents and Short-Term Investments3.32B3.90B4.79B5.58B2.94B3.34B
Total Debt000000
Total Liabilities354.46M353.83M211.91M200.96M133.79M149.36M
Stockholders Equity4.44B4.75B5.53B5.98B3.45B3.90B
Cash Flow
Free Cash Flow0-1.10B-892.81M-474.83M-412.18M-249.45M
Operating Cash Flow0-1.06B-812.62M-451.06M-401.61M-220.76M
Investing Cash Flow0-7.59M-117.99M-33.50M-8.97M-28.44M
Financing Cash Flow0176.84M143.11M3.12B10.69M48.54M

Cuorips Inc. Technical Analysis

Technical Analysis SentimentNegative
Last Price5600.00

Price Trends

50DMA6191.20Negative
100DMA5472.80Positive
200DMA6102.93Negative

Market Momentum

MACD-12.26Positive
RSI38.06Neutral
STOCH24.73Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4894, the sentiment is Negative. The current price of 5600.00 is below the 20-day moving average (MA) of 6635.50, below the 50-day MA of 6191.20, and below the 200-day MA of 6102.93, indicating a bearish trend. The MACD of -12.26 indicates Positive momentum. The RSI at 38.06 is Neutral, neither overbought nor oversold. The STOCH value of 24.73 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4894.

Cuorips Inc. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

JP:4894 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
JP:4894JP:489444NeutralJPY 49.73B-43.41――-79.99%-58.51%
JP:4978JP:497842NeutralJPY 11.33B-24.37――-8.23%-48.10%
JP:7774JP:777442NeutralJPY 26.32B-73.22――17.05%10.47%
JP:4599JP:459938UnderperformJPY 7.65B-4.11―――4.85%
JP:4593JP:459337UnderperformJPY 27.79B-12.37――-51.55%52.19%
JP:7776JP:777637UnderperformJPY 6.15B-5.03――-49.43%-3.77%

* General Sector Average

Performance Comparison

-50%0%50%JP:4894JP:4593JP:4599JP:4978JP:7774JP:7776Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
JP:4894 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
JP:4894Cuorips Inc.5600.00-590.00-9.53%
JP:4593Healios KK205.00-281.00-57.82%
JP:4599StemRIM Inc.122.00-155.00-55.96%
JP:4978ReproCELL Inc.106.00-54.00-33.75%
JP:7774Japan Tissue Engineering Co., Ltd.648.00169.0035.28%
JP:7776CellSeed Inc.155.00-224.00-59.10%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 23, 2026